SelectQuote, Inc. (SLQT) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects mixed signals: stable PBM reimbursement and positive Medicare Advantage outlook are balanced by IRA-induced revenue decline and cautious guidance. The Q&A reveals management confidence in achieving EBITDA targets and operational efficiencies, yet lacks detailed metrics on valuation concerns. Flat membership growth and guidance adjustments suggest limited short-term stock movement. Without market cap data, a neutral prediction is prudent.
Key Financial Performance
Revenue $431 million, a 6% year-over-year growth driven by strong performance in Senior and Healthcare Services segments.
Adjusted EBITDA $45 million, an 18% year-over-year growth, aided by a positive change in estimate to commissions receivable.
Senior Revenue $183 million, an 8% year-over-year growth driven by healthier OEP, strong agent productivity, customer retention, and a positive change to commissions receivables.
Senior Adjusted EBITDA $59 million, including a $14 million positive adjustment to commissions receivable. Excluding the adjustment, the EBITDA margin was 26%.
Healthcare Services Revenue $199 million, a 5% year-over-year growth. Growth was impacted by carrier-specific actions on reimbursement and the implementation of the Inflation Reduction Act.
Healthcare Services Adjusted EBITDA $5 million, improved sequentially despite headwinds from the Inflation Reduction Act and carrier-specific actions.
Life Insurance Revenue $48 million, a 4% year-over-year growth driven by strong demand for Final Expense products, partially offset by challenges in Term Life.
Life Insurance Adjusted EBITDA $6 million, reflecting steady profitability and cash flow contribution.
Medicare Advantage Commissions Receivable Nearly $1 billion, reflecting a strong balance sheet asset and future cash flow potential.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SelectQuote Local Initiative: A new franchise model allowing local community healthcare and life insurance participants to leverage SelectQuote's marketing, technology, products, and customer service platform. This initiative broadens reach and addressable market but is not expected to be a significant revenue driver in the near term.
Senior Segment Growth: Revenue grew by 8% year-over-year to $183 million, driven by healthier OEP, strong agent productivity, and customer retention. Adjusted EBITDA for the Senior segment totaled $59 million, with a 26% margin excluding adjustments.
Healthcare Services Expansion: Revenue grew 5% year-over-year to $199 million, with membership growth of 11%. Adjusted EBITDA improved sequentially to $5 million despite headwinds from the Inflation Reduction Act and carrier-specific reimbursement actions.
Operational Efficiency in Senior Segment: Improved agent productivity and marketing efficiency, with a 14% reduction in marketing spend per approved policy compared to two years ago.
SelectRx Operational Efficiency: 64% increase in prescriptions shipped compared to two years ago, driven by improved operating efficiency at the Olathe, Kansas distribution facility, which achieved 30%+ efficiency gains.
Focus on Cash Flow and Profitability: The company is prioritizing cash flow generation and aims to deliver significant year-over-year improvement in operating cash flow in fiscal 2026, with further growth expected in fiscal 2027.
Equity Value Disconnect: Management highlighted a significant disconnect between the company's equity market value and the real value of its cash flows, emphasizing efforts to address this issue.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Healthcare Services Revenue Impact: Revenue and profitability in SelectRx were impacted by carrier-specific actions on reimbursement and the implementation of the Inflation Reduction Act, which set maximum fair prices for certain drugs. This led to a sequential drop in revenue and a low single-digit million-dollar impact on EBITDA.
Medicare Advantage Ecosystem Challenges: The Medicare Advantage backdrop was described as mixed, with potential timing-related impacts on policy approvals that could affect future quarters. This creates uncertainty in revenue and policy growth projections.
Equity Market Valuation Disconnect: The company highlighted a significant disconnect between its equity market valuation and the perceived value of its cash flow streams and balance sheet assets, which could impact investor confidence and stock performance.
Operational Efficiency Risks: While the Olathe distribution facility has shown efficiency gains, it currently operates at less than half capacity and runs only one shift. Scaling operations effectively without disruptions remains a challenge.
Regulatory and Competitive Pressures in Life Insurance: The Term Life insurance market remains competitive, with shifting consumer behavior in media consumption affecting demand. This could impact revenue growth in this segment.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Fiscal 2026 Outlook: The company reaffirms its outlook for fiscal 2026, emphasizing its goal to drive profitability and cash flow.
Fiscal 2027 Projections: SelectQuote is well-positioned to accelerate cash flow expansion in fiscal 2027, with Healthcare Services expected to be a significant driver of profitable cash flow growth.
Medicare Advantage Ecosystem: The company anticipates increasing visibility and stability within the Medicare Advantage ecosystem in 2027, which is expected to support cash flow growth.
SelectQuote Local Initiative: The company introduced SelectQuote Local, a franchise model aimed at expanding its reach and addressable market. While not expected to be a meaningful revenue driver in the near term, it is strategically significant for long-term growth.
Healthcare Services Efficiency: The Olathe distribution facility is expected to drive significant cost efficiencies, with plans to scale operations and increase utilization in the coming quarters.
Life Insurance Segment: Final Expense product is expected to remain a consistent growth driver with highly attractive margins.
Revenue and Adjusted EBITDA Guidance: The company reaffirmed its revenue guidance of $1.61 billion to $1.71 billion and adjusted EBITDA guidance of $90 million to $100 million for fiscal 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the current state of the PBM reimbursement environment for SelectRx?
A:The PBM reimbursement environment remains stable. The company resolved earlier challenges with reimbursement rates, and rates have normalized in the third quarter. A multi-year agreement with the largest PBM partner has been secured.
Q:What impact did the Inflation Reduction Act (IRA) have on revenue for the quarter?
A:The IRA caused a sequential revenue decline, but the bottom-line impact was different due to $13 million in refunds from drug manufacturers, which flowed through the cost of goods line item. The revenue decline was fully accounted for in the guidance.
Q:What are the company's plans to accelerate cash flow dynamics by 2027?
A:The company is making progress year-over-year due to positive changes in capital structure and cash interest obligations. Key factors include improved efficiency in the Senior distribution business, agent productivity, marketing efficiency, and operational improvements at the Kansas City facility, which is driving 30%+ efficiency compared to legacy pharmacies.
Q:What is the company's outlook on the Medicare Advantage ecosystem?
A:The company sees positive developments in the broader Medicare Advantage market recovery but remains cautious about the pace. Medical cost trends are easing slightly, but reimbursement trends are not fully sufficient to cover costs. Changes to star ratings are seen as a positive tailwind, and the company anticipates potential disruption in the next year as carriers target margin goals. The company remains cautiously optimistic.
Q:What steps is the company taking to address the disconnect in its equity valuation?
A:The company plans to ensure it remains listed on the New York Stock Exchange and is evaluating various options, including capital markets transactions, securitization, and potential M&A. The company believes consolidation in the market might make sense and sees itself as a strong player in a consolidating market.
Q:Does the company expect SelectRx to achieve a $40 million to $50 million EBITDA run rate by year-end?
A:Yes, the company is highly confident that SelectRx will achieve a $40 million to $50 million EBITDA run rate in the near term, driven by operational efficiencies at the Kansas City facility.
Q:How does the company plan to manage volumes across its facilities, including Kansas City?
A:The company is working on a new pharmacy management system to handle more volume. Moving volumes to Kansas City is expected to enhance margins in other facilities by reducing burdens like late-night shifts. The Kansas City facility is driving significant cost savings.
Q:What is the source of the $14 million positive change in estimate for Senior?
A:The $14 million positive change in estimate is due to enhanced visibility into the book of business and better-than-expected persistency. It is not tied to a specific cohort but reflects broader adjustments based on expectations. The company is not modifying guidance at this time.
Q:What factors impact the LTV calculation, and how might it improve?
A:Factors impacting LTV include customer retention, carrier mix, and payment structures. Increased stability in the Medicare system would be a tailwind for LTV. The company has navigated disruptive Medicare seasons well and hopes for increased stability in the future.
Q:Have there been any changes in carrier marketing spend?
A:No significant changes in carrier marketing spend have been observed beyond what was shared in the second quarter. Carriers will go through annual planning cycles in the summer, and the company expects to provide more clarity in its fiscal 2027 guidance.
Q:How is the company performing in the back half of the year, particularly in the Senior segment?
A:The company performed well during the OEP period and is seeing similar trends in the SEP period compared to last year. The year-round model and SelectRx contribute to strong enterprise economics, even during quieter periods like SEP.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on how they plan to remedy the disconnect in equity valuation beyond ensuring the company remains listed on the NYSE and evaluating options like securitization and M&A. Additionally, while they mentioned operational efficiencies and cost savings, they did not provide detailed metrics or timelines for these initiatives.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act detail
Advantage backdrop
Advantage balance
Advantage ecosystem
Agent service
Americans scale
CAC Healthcare
CAC multiple
Exchange stock
IPO SelectQuote
Inflation Reduction
Local extension
OEP
SelectQuote Local
SelectRx member
action
adjustment
agent productivity
balance sheet
commission
conviction
disconnect
equity
extension model
future
goal
headwind
onboarding
page
people
receivables
result segment
return
sheet asset
valuation
visibility
SLQT Transcript
SelectQuote, Inc. (SLQT) Q3 2026 Earnings Call Transcript
Unknown5-5
The earnings call reflects mixed signals: stable PBM reimbursement and positive Medicare Advantage outlook are balanced by IRA-induced revenue decline and cautious guidance. The Q&A reveals management confidence in achieving EBITDA targets and operational efficiencies, yet lacks detailed metrics on valuation concerns. Flat membership growth and guidance adjustments suggest limited short-term stock movement. Without market cap data, a neutral prediction is prudent.
SelectQuote, Inc. (SLQT) Q2 2026 Earnings Call Transcript
Positive2-5
The earnings call reveals strong financial performance, with a 12% revenue growth and 26% increase in Healthcare Services revenue. The company maintains a stable fiscal 2026 outlook and anticipates positive cash flow. Despite increased competition in life insurance, the company has strong operational execution and marketing efficiency. The new PBM deal offers stability, and the strategic plan for Medicare Advantage is promising. The Q&A section supports management's confidence, with positive analyst sentiment, suggesting a likely positive stock price movement in the short term.
SelectQuote, Inc. (SLQT) Q1 2026 Earnings Call Transcript
Unknown11-6
The earnings call reflects several challenges: increased costs in the Life Insurance division, dependence on SelectRx amidst reimbursement headwinds, and a decline in Senior segment revenues and EBITDA. Despite revenue growth, the company faces significant short-term financial hurdles, with a negative quarterly EBITDA and declining policy production. The Q&A section reveals uncertainty in reimbursement rate improvements and vague management responses, further dampening sentiment. Without a clear positive catalyst or partnership announcement, these factors collectively suggest a negative stock price reaction in the short term.
SelectQuote, Inc. (SLQT) Q4 2025 Earnings Call Transcript
Unknown8-21
The earnings call presents mixed signals: while there is growth in SelectRx membership and improved EBITDA margins, revenue and Medicare Advantage policies declined. Management's focus on EBITDA and margin expansion over rapid growth, along with AI investments, is positive. However, lower revenue and strategic agent staffing choices raise concerns. Q&A insights do not significantly alter the sentiment, as there are no major catalysts or risks highlighted. Given the lack of market cap data, a neutral stock price movement is predicted.
SLQT Slides
SLQT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
